This is the third and final installment of a series of articles discussing cannabinoid-rich hemp oil and a new certification program for dietary supplement manufacturers and healthcare practitioners offered by the International Center for Cannabis Therapy (ICCT). As Chief Medical Officer–USA of the ICCT, a Czech Republic-based partnership of qualified doctors and scientists who specialize in the medical application of cannabis, Dr. Meletis is an expert on the clinical applications and research supporting the use of cannabinoid-rich hemp oil and its effects on the endocannabinoid system.Meletis 4
The scientific evidence is compelling!
The peer-reviewed journal, Alternative Therapies in Health and Medicine, recently published the results of a double-blind study comparing the bioavailability of patented CoQsource Bio-Enhanced CoQ10 to that of other bio-enhanced formulations. The study, entitled, “Relative Bioavailability Comparison of Different Coenzyme Q10 Formulations with a Novel Delivery System,” appears in the March/April, 2009 issue, Volume 15, Number 2.
The graph shows a pharmacokinetic study (single oral dose, crossover) in humans comparing VESIsorb® CoQsource® to the same standard Coenzyme Q10 in different formulation demonstrating an increase of absorption in peak blood levels. The relative bioavialiability of a single oral dose of 120mg of CoQ10 was asserted using the AUC. The results showed 622% higher bioavialiability than the oil-based formula and 499% higher bioavialiability than the solubilizate.
The single oral 120 mg does of the VESIorb® – CoQ10 resulted in a peak plasma level of 6.89 μg/mL compared to 2.24 μg/mL achieved with 120 mg of an oil-based formula.
Analysis of the area under the curve revealed the relative bioavailability of VESIsorb® – CoQ10 was up to 622% compared to the other formulations studied.